Oruka Therapeutics, Inc. ORKA EPS (Diluted)
Discontinued — last reported Q2 '25
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed August 11, 2025, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s EPS (diluted)?
- Oruka Therapeutics, Inc. (ORKA) reported EPS (diluted) of -$0.46 in Q2 2025.
- How has Oruka Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Oruka Therapeutics, Inc.'s EPS (diluted) increased by 93.4% year-over-year, from -$6.96 to -$0.46.
- What is the long-term trend for Oruka Therapeutics, Inc.'s EPS (diluted)?
- Over 3 years (2021 to 2024), Oruka Therapeutics, Inc.'s EPS (diluted) has grown at a 118.0% compound annual growth rate (CAGR), from -$1.40 to -$14.50.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.